Triptorelin (pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2) is a decapeptide GnRH (LHRH) agonist used to treat men with prostate cancer, women who have uterine fibroids or endometriosis, and boys and girls when puberty occurs prematurely. This peptide acts as a gonadotopin-releasing hormone agonist by stimulating the pituitary gland resulting in a decrease in a release of follicle stimulating and luteinizing hormones. Triptorelin is sold under the trade names Trelstar by Watson Pharmaceuticals and Diphereline by Ferring Pharmaceuticals.
|PRODUCT NAME:||Triptorelin Acetate|
|CAS REGISTRY NUMBER:||[57773-63-4]|
|SYNONYMS:||Decapeptyl, Diphereline, Gonapeptyl, and Trelstar|
|CLINICAL AREA:||Assisted Reproduction, Cancer|
|DMF SCHEDULE:||CFDA: 3/2014|